Caprock Group LLC Boosts Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Caprock Group LLC lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,304 shares of the company’s stock after purchasing an additional 2,454 shares during the quarter. Caprock Group LLC’s holdings in Takeda Pharmaceutical were worth $488,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in shares of Takeda Pharmaceutical by 65.2% during the 1st quarter. Russell Investments Group Ltd. now owns 10,676 shares of the company’s stock worth $148,000 after buying an additional 4,213 shares during the last quarter. Blair William & Co. IL increased its stake in Takeda Pharmaceutical by 6.5% during the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock worth $176,000 after acquiring an additional 777 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in Takeda Pharmaceutical by 43.2% in the first quarter. O Shaughnessy Asset Management LLC now owns 88,663 shares of the company’s stock valued at $1,232,000 after purchasing an additional 26,735 shares during the period. Pitcairn Co. acquired a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at $197,000. Finally, Advisors Asset Management Inc. grew its holdings in shares of Takeda Pharmaceutical by 7.1% during the 1st quarter. Advisors Asset Management Inc. now owns 49,781 shares of the company’s stock worth $691,000 after purchasing an additional 3,315 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.4 %

Shares of TAK opened at $13.38 on Friday. The company’s 50-day moving average price is $14.10 and its 200 day moving average price is $13.83. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The firm has a market cap of $42.57 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.